专利号:US-2012165520-A1 优先权日:2010-12-23 标题:Process for the synthesis of prodrugs of opioids 发明人:MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS 权利人:MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS 摘要:The present invention provides a process for the synthesis of opioid prodrugs. In particular, the present invention provides a process for the synthesis of opioid prodrugs comprising: treating an opioid, in the form of a salt or a freebase, with a carbonyl synthon to form an activated intermediate and subsequently reacting the activated intermediate with an amine, in the form of a salt or a freebase.
专利号:US-9643915-B2 优先权日:2013-03-15 标题:Methods for the synthesis of sphingomyelins and dihydrosphingomyelins 发明人:ONICIU DANIELA CARMEN; HECKHOFF STEFAN; OSWALD BENOIT; REBMANN PETER; PEER ANDREAS; GONZALEZ MIGUEL; SAUTER PATRIK 权利人:CERENIS THERAPEUTICS HOLDING SA 摘要:The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.
专利号:US-9708354-B2 优先权日:2013-03-15 标 题:Methods for the synthesis of sphingomyelins and dihydrosphingomyelins 发明人:ONICIU DANIELA CARMEN; HECKHOFF STEFAN; OSWALD BENOIT; REBMANN PETER; PEER ANDREAS; GONZALEZ MIGUEL; SAUTER PATRIK 权利人:CERENIS THERAPEUTICS HOLDING SA 摘要:The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.
专利号:WO-2016171538-A1 优先权日:2015-04-22 标 题 :Enzymatic-chemical method for the synthesis of vanillylamides of organic acids 发明人:TORRES GAVILÃ?N ALEJANDRO; REGLA CONTRERAS JOSÉ IGNACIO; CASTILLO ROSALES EDMUNDO; LÓPEZ-MUNGUÃ?A CANALES AGUSTÃ?N 权利人:UNIV NAC AUTÓNOMA DE MÉXICO 摘要:The invention relates to a method for synthesising vanillylamides of organic acids, based on vanillin oxime, inorganic salts of vanillylamine or based on organic salts of vanillylamine having organic acids. The method involves: the chemical synthesis of vanillylamine organic salts based on the hydrogenation of the vanillin oxime in the presence of an organic acid; the release of vanillylamine inorganic salts in the presence of a base or carbonate and an organic acid; and an enzymatic condensation of the two elements that form the organic salt, the vanillylamine and the organic acid, in order to bring about the synthesis of organic acid vanillylamides. The organic acid used for the reaction can be any organic acid: natural or synthetic, saturated, linear or branched, having substituents such as hydroxyl groups or others. The reactions can be carried out independently or in sequence. These capsaicinoid compounds, components similar to capsaicin or vanillylamides can be used as a pungent material, irritant, in pharmaceutical products, as additives in food, in cosmetics, among others.
专利号:WO-2004011474-A1 优先权日:2002-07-31 标题:Universal support media for synthesis of oligomeric compounds 发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K 权利人:ISIS PHARMACEUTICALS INC; GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K 摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotide and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.
专利号:US-6653468-B1 优先权日:2002-07-31 标 题 :Universal support media for synthesis of oligomeric compounds 发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH 权利人:ISIS PHARMACEUTICALS INC 摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.
1: Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013 Aug 9;288(32):23447-56. doi: 10.1074/jbc.M113.475798. Epub 2013 Jun 18. Erratum in: J Biol Chem. 2013 Oct 4;288(40):28951. 2: Chakraborty S, Gruber T, Barry CE 3rd, Boshoff HI, Rhee KY. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science. 2013 Jan 4;339(6115):88-91. doi: 10.1126/science.1228980. Epub 2012 Nov 1. 3: Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis. 2015 Sep;15(9):1091-9. doi: 10.1016/S1473-3099(15)00263-7. Epub 2015 Aug 12. Review. doi: 10.1007/s40261-014-0172-7. doi: 10.1093/tropej/fms053. Epub 2012 Nov 21. doi: 10.1038/aps.2014.103. Epub 2014 Nov 24.
合成参考文献
参考文献:10.1111/j.1747-0285.2011.01179.x 摘要:Zhang J, Shan Y, Pan X, Wang C, Xu W, He L. Molecular Docking, 3D‐QSAR Studies, and In Silico ADME Prediction of p‐Aminosalicylic Acid Derivatives as Neuraminidase Inhibitors. Chem Biol Drug Des. 2011 Sep 06;78(4):709–17. doi: 10.1111/j.1747-0285.2011.01179.x. 摘要:Ou CY, Huang ML, Jiang YM, Luo HL, Deng XF, Wang C, Wang F, Huang XW. [Effect of sodium para-aminosalicylic on concentrations of amino acid neurotransmitters in basal ganglia of manganese-exposed rats]. Zhonghua Yu Fang Yi Xue Za Zhi. 2011 May;45(5):422–5. 参考文献:10.1124/dmd.111.040915 摘要:Hong L, Jiang W, Pan H, Jiang Y, Zeng S, Zheng W. Brain Regional Pharmacokinetics of p-Aminosalicylic Acid and Its N-Acetylated Metabolite: Effectiveness in Chelating Brain Manganese. Drug Metabolism and Disposition. 2011 Oct;39(10):1904–9. doi: 10.1124/dmd.111.040915. 参考文献:10.4081/pr.2011.e16 摘要:Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011 Jun 16;3(2):e16.